CSIMarket
 


Organogenesis Holdings Inc   (NASDAQ: ORGO)
 

Organogenesis Holdings Inc 's Revenue per Employee

Quarterly Results, Trends, Rankings, Statistics, Cumulative Sales


Organogenesis Holdings Inc 's Revenue per employee fell on a trailing twelve month basis to $ 602,698, but the productivity of Organogenesis Holdings Inc 's employees remained above the company average.
Within the Healthcare sector Employees of 100 other companies have achieved higher revenue per employee. While Organogenesis Holdings Inc 's total ranking has deteriorated compared to the previous quarter from 823 to 1008. Organogenesis Holdings Inc has 854 employees.


What is Sales per Employee Ratio?







ORGO Revenue per Employee (Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
(Mar 31 2025)
I. Quarter
Y / Y Revenue Change -57.06 % 78.13 % 30.98 % -22.44 % -21.17 %
Sales per Employee (TTM) $ 602,698 660,619 544,752 502,964 537,190
ORGO's Total Ranking # 1008 # 823 # 1480 # 1422 # 1243
Seq. Revenue Change -83.5 % 49.54 % 49.36 % 16.51 % -31.55 %


Revenue per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 66
Healthcare Sector # 101
Overall Market # 1008

Revenue per Employee Statistics
High Average Low
$ 660,619 $ 498,106 $ 305,598
(Dec 31 2025)   (Dec 31 2019)



Financial Statements
Organogenesis Holdings Inc 's Revenue MRQ $ 37 Millions Visit ORGO's Income Statement
Organogenesis Holdings Inc 's Revenues TTM $ 515 Millions Visit ORGO's aggregate revenue growth
What are ORGO's Sales? Visit ORGO's Sales by Segment


  News about Organogenesis Holdings Inc Revenue per employee

Organogenesis Navigates Funding Gaps and Policy Shifts Amidst Record High Revenue: A Dual Focus on Growth and Patient-Centric Solutions

In an era where healthcare innovation is paramount, Organogenesis Holdings Inc. finds itself at a critical crossroads. As the company pushes for a delay in the Centers for Medicare and Medicaid Services (CMS) Local Coverage Determination (LCD) implementation, it seeks to bolster its commitment to patient access and the strength of medical evidence supporting its treatments. However, this advocacy comes against the backdrop of a significant financial struggle that raises questions about the firm’s sustainability and future in a competitive landscape. A Shift in Coverage and Payment Policy Organogenesis, a company specializing in regenerative medicine, has advocated for “an integrated coverage and payment policy” as it endeavors to ensure that patients have access to its innovative therapies. The recent push for a delay in the LCD implementation underscores the company’s desire to review existing coverage policies more thoroughly. By requesting this postponement, Organogenesis aims to assure the healthcare system that its treatments not only meet regulatory standards but are also backed by substantial evidence of effectiveness.




Other Ratios
Organogenesis Holdings Inc 's Income per Employee
Employees in Major Pharmaceutical Preparations
Major Pharmaceutical Preparations Industry Revenue per Employee Trends and Statistics
Healthcare Sector Revenue per Employee Statistics
Revenue per Employee Trends for overall market
ORGO's Revenue per Employee versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue per Employee
Lowest Ranking Revenue per Employee
Revenue per Employee for ORGO's Competitors
Revenue per Employee for ORGO's Suppliers
Revenue per Employee for ORGO's Customers

You may also want to know
ORGO's Sales Growth Rates ORGO's Pe Price to earnings ratio ORGO's Receivables Turnover Ratio ORGO's Stock Quote
ORGO's Net Income Growth Rates ORGO's Ps Price to Sales ratio ORGO's Sales per Employee ORGO's Asset Turnover Ratio
ORGO's Net Margin ORGO's Pb Price to Book ratio ORGO's Financial Strength Ratios ORGO's Dividend Payout Ratio
Date modified: 2026-08-29T17:37:45+00:00




Companies with similar Revenue per Employee for 12 months ending Mar 31 2026, within Healthcare Sector Revenue per Employee Revenue 12 months ending Mar 31 2026Number of Employees Mar 31 2026
Corcept Therapeutics Inc  1,053,556.16 $ 769.096  Million 730 
Biomarin Pharmaceutical Inc  1,006,617.82 $ 3,242.316  Million 3,221 
Scilex Holding Company  995,941.18 $ 33.862  Million 34 
Coya Therapeutics Inc   992,377.00 $ 7.939  Million
Sanara Medtech Inc   989,563.23 $ 106.873  Million 108 
Assembly Biosciences Inc   973,931.51 $ 71.097  Million 73 
Hims and Hers Health Inc   970,301.39 $ 2,369.476  Million 2,442 
Regeneron Pharmaceuticals Inc   968,176.51 $ 14,919.600  Million 15,410 
Ani Pharmaceuticals Inc  952,274.23 $ 923.706  Million 970 
Integrated Biopharma Inc  944,820.00 $ 47.241  Million 50 
Evolus Inc   905,236.53 $ 302.349  Million 334 
Pacira Biosciences inc   886,446.32 $ 734.864  Million 829 
Keenova Therapeutics Plc  883,125.00 $ 1,413.000  Million 1,600 
Nektar Therapeutics  883,063.49 $ 55.633  Million 63 
Merck and Co Inc   876,906.67 $ 65,768.000  Million 75,000 
Arrowhead Pharmaceuticals Inc   874,836.85 $ 622.009  Million 711 
Ardelyx inc   874,599.18 $ 427.679  Million 489 
Lifevantage Corp  868,242.15 $ 193.618  Million 223 
Prothena Corporation Public Limited Company  864,776.12 $ 57.940  Million 67 
Alphatec Holdings Inc   861,301.20 $ 786.368  Million 913 
Lexicon Pharmaceuticals Inc   859,790.12 $ 69.643  Million 81 
The Oncology Institute Inc   851,425.90 $ 545.764  Million 641 
Fortress Biotech Inc   848,217.95 $ 66.161  Million 78 
Pfizer Inc  844,200.00 $ 63,315.000  Million 75,000 
Carlisle Companies Incorporated  843,423.73 $ 4,976.200  Million 5,900 
Ptc Therapeutics inc   834,621.59 $ 827.110  Million 991 
Sanuwave Health Inc   805,963.64 $ 44.328  Million 55 
Xtant Medical Holdings Inc   801,331.13 $ 121.001  Million 151 
Novavax inc   796,178.91 $ 596.338  Million 749 
Marker Therapeutics inc   789,851.20 $ 3.949  Million




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.